SynthesisThe Cochrane database of systematic reviews2013
Cerebrolysin for vascular dementia.
Synthesis in The Cochrane database of systematic reviews, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 91 citations in OpenAlex.
- Cerebrolysin for vascular dementia.The Cochrane database of systematic reviews · 2019Pooled it
- Cerebrolysin for acute ischaemic stroke.The Cochrane database of systematic reviews · 2017Pooled it
- Cerebrolysin for acute ischaemic stroke.The Cochrane database of systematic reviews · 2016Pooled it
- Randomized, placebo-controlled, double-blind, pilot trial to investigate safety and efficacy of Cerebrolysin in patients with aneurysmal subarachnoid hemorrhage.BMC neurology · 2020Trial
- Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.International journal of molecular sciences · 2026Review
- Is Cerebrolysin Useful in Psychiatry Disorders?Biomedicines · 2025Article
- Cerebrolysin induces hair repigmentation associated to MART-1/Melan-A reactivation.European journal of medical research · 2022Article
- The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis.Cerebral circulation - cognition and behavior · 2021Article
- Cerebroprotein Hydrolysate-I Inhibits Hippocampal Neuronal Apoptosis by Activating PI3K/Akt Signaling Pathway in Vascular Dementia Mice.Neuropsychiatric disease and treatment · 2021Article
- Neuroprotective action of Cortexin, Cerebrolysin and Actovegin in acute or chronic brain ischemia in rats.PloS one · 2021Article
- Cerebral Small Vessel Disease (CSVD) - Lessons From the Animal Models.Frontiers in physiology · 2019Review
- Towards the concept of disease-modifier in post-stroke or vascular cognitive impairment: a consensus report.BMC medicine · 2017Article
- Effects of cerebrolysin on nerve growth factor system in the aging rat brain.Restorative neurology and neuroscience · 2017Article
- Altering the course of schizophrenia: progress and perspectives.Nature reviews. Drug discovery · 2016Review
- Chronic administration of isocarbophos induces vascular cognitive impairment in rats.Journal of cellular and molecular medicine · 2016Article
- Porcine prion protein amyloid.Prion · 2015Article
- Vascular cognitive impairment and post-stroke cognitive deficits.Current neurology and neuroscience reports · 2014Review
- Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke.Neuropsychiatric disease and treatment · 2014Article
- The pathobiology of vascular dementia.Neuron · 2013Review
- Vascular aspects of cognitive impairment and dementia.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2013Review
Corrections and comments
- Updated by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVascular dementia is a common disorder without definitive treatments. Cerebrolysin seems to be a promising intervention based on its potential neurotrophic and pro-cognitive effects, but studies of its efficacy have yielded inconsistent results.
objectivesTo assess the efficacy and safety of Cerebrolysin for vascular dementia. SEARCH
methodsWe searched ALOIS - the Cochrane Dementia and Cognitive Improvement Group's Specialized Register on 4 November 2012 using the terms: Cerebrolysin, Cere, FPF1070, FPF-1070. ALOIS contains records of clinical trials identified from monthly searches of a number of major healthcare databases, numerous trial registries and grey literature sources. SELECTION CRITERIA: All randomized controlled trials of Cerebrolysin for treating vascular dementia without language restriction. DATA COLLECTION AND ANALYSIS: Two authors independently selected trials and evaluated the methodological quality, then extracted and analysed data from the included trials. MAIN
resultsSix randomized controlled trials with a total of 597 participants were eligible. The meta-analyses revealed a beneficial effect of Cerebrolysin on general cognitive function measured by mini-mental state examination (MMSE) (weighted mean difference (WMD) 1.10; 95% confidence interval (CI) 0.37 to 1.82) or Alzheimer's Disease Assessment Scale Cognitive Subpart, extended version (ADAS-cog+) (WMD -4.01; 95% CI -5.36 to -2.66). It also improved patients' global clinical function evaluated by the response rates (relative risk (RR) 2.71, 95% CI 1.83 to 4.00). Only non-serious adverse events were observed in the included trials, and there was no significant difference in occurrence of non-serious side effects between groups (RR 0.97, 95% CI 0.49 to 1.94). AUTHORS'
conclusionsCerebrolysin may have positive effects on cognitive function and global function in elderly patients with vascular dementia of mild to moderate severity, but there is still insufficient evidence to recommend Cerebrolysin as a routine treatment for vascular dementia due to the limited number of included trials, wide variety of treatment durations and short-term follow-up in most of the trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.